Oxandrolone in Healthy Adults: A Relative Bioavailability Study

University of Utah6 enrolled

Overview

To assess the pharmacokinetics and relative bioavailability of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil oxandrolone solution vs. tablets in a small cohort of healthy adults.

The results of this study will provide data regarding the relative bioavailability of a novel preparation of oxandrolone in MCT oil, which will allow dosing in neonates and small infants. This pilot study will provide information to design a larger multicenter study of neonates undergoing surgery for complex congenital heart disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bioavailability

Interventions

OxandrinDRUG

The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints. Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male 2. Age 18 to 35 years (inclusive) at the time of screening 3. Body mass index \[BMI, body weight (kg)/height (m)2\] below 30 kg/m2 4. Medically healthy Exclusion Criteria: 1. Known allergy to anabolic steroids 2. Use of any prescription medication currently or within 14 days prior to dosing 3. Use of tobacco or nicotine containing products (including smoking cessation products), within 6 months prior to dosing 4. Any chronic medical condition 5. Seated blood pressure \<90/40 mmHg or \>140/90 mmHg at screening 6. Heart rate \<40 or \>99 at screening 7. Subjects who have taken any investigational drug within 30 days prior to first dose in the current study

Locations (1)

Primary Children's Hospital

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Peak Plasma Concentration (Cmax) curve

The primary outcome for this study will be the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation as measured by peak plasma concentration (Cmax) curve

Time frame: Measurement of Peak Plasma Concentration (Cmax) at 15 min, 30 min, 1, 2, 3, 4, 8, 24, 48 hours on Days 1 and 8

Area under the plasma concentration versus time curve (AUC)

The primary outcome for this study will be the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation as measured by the area under the plasma concentration versus time curve (AUC).

Time frame: Measurements at 15 min, 30 min, 1, 2, 3, 4, 8, 24, 48 hours on Days 1 and 8

Secondary Outcomes

Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing.

The risks associated with the 2 doses of oxandrolone given during the course of this study are minimal. Known adverse effects of anabolic steroids, including hepatic dysfunction and virilization, are typically associated with longer-term use (months of daily dosing) and are very unlikely to occur in this study.

Time frame: Liver function will be assessed by measuring serum transaminase levels at baseline and 1 week after each oxandrolone dose in the study participants, and any adverse events throughout the study period and up to 1 week after final dosing will be recorded.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.